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achieved by analytically determining
the amount of calcium in chelexed fetal
bovine serum (FBS) and then adding 1M
calcium chloride to 10% FBS/calcium-
free DMEM to achieve a final concen-
tration of 50 mM Ca2þ . In addition,
following the 45minutes incubation in
50 mM calcium media was a second
incubation for 30–45minutes in dispase
II to detach the epithelial sheets from
the substrate. This solution lacked
calcium. Thus, in our assay cells were
incubated in total for 75–90minutes in
reduced or calcium-free conditions.
The low-calcium medium used in our
report mirrors that described by Mattey
and Garrod (1986). In this report, the
authors demonstrated that cells switched
back into 50mM calcium-containing med-
ium after having been in normal calcium
for a period of days to weeks (depending
on cell type) lose their desmosomes from
the surface within 15–30minutes in a
manner similar to that exhibited by cells
treated with EGTA. Desmosomes even-
tually became resistant to the reduction in
calcium, whether using chelators or using
low-calcium medium, a state for which
the term ‘‘hyperadhesion’’ was more
recently coined. We have also observed
the loss of desmosomes from the surfaces
of the squamous cell carcinoma and A431
cells used in Hobbs and Green (2012)
within 15–30 minutes in 50mM calcium-
containing medium (data not shown).
In Hobbs and Green (2012), we
embraced the concept of ‘‘hyperadhe-
sion’’ coined by Garrod (2005) as a
regulatory mechanism that can dictate
epidermal function and plasticity. Con-
tending that the use of EGTA is essential
to assess the hyperadhesive state sug-
gests that different mechanisms may
underlie the increased adhesion
strength observed in cells incubated in
low calcium versus EGTA. If this were
the case, then it follows that there
may be strong states of adhesion that
are distinct from ‘‘hyperadhesion’’.
Because the underlying mechanisms
driving hyperadhesion are not known,
we cannot directly refute this argu-
ment. What we can say is that desmo-
somes containing phospho-deficient
desmoplakin undergo accelerated ac-
quisition of a super-strong adhesive
state resistant to both reduced calcium
and to PKC activation, which are
attributes one would predict if desmo-
plakin were regulating desmosome hy-
peradhesion.
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TO THE EDITOR
Recent molecular classification of mel-
anomas has revealed that BRAF and
NRAS mutations are common in mela-
nomas on skin without chronic sun-
induced damage (non-CSD melanoma),
whereas KIT mutations and/or in-
creased copy number are frequently
found in mucosal and acral melanomas
(Davies et al., 2002; Curtin et al., 2005,
2006). Most previous studies have been
conducted in Caucasian populations,
which show different common melano-
ma subtypes compared with Asian
populations. Mutation status may also
be different in Asian populations,
although few studies have examined
BRAF and KIT mutations in Asian mela-
nomas (Ashida et al., 2009; Terada,
2010; Kong et al., 2011; Yun et al.,
2011; Si et al., 2012). In the presentAbbreviation: CSD, chronic sun-induced damage
www.jidonline.org 579
SA Jin et al.
BRAF Mutations and KIT Aberrations
Table 1. Cox proportional HRs for clinicopathological features, BRAFmutations, and KIT aberrations in 202 Korean
melanomas
Feature
Median survival
(months)
Unadjusted HR
(95% CI; P-value)1 P for trend
Fully adjusted HR
(95% CI; P-value)1 P for trend
Age 25.2 1.01 (0.99–1.01; 0.297)
Sex
Male 39.7 1.00 (reference)
Female 47.0 0.73 (0.50–1.07; 0.732)
Breslow thickness o0.001
T1 103.7 1.00 (reference)
T2 88.3 1.17 (0.46–2.97; 0.746)
T3 53.2 1.74 (0.78–3.89; 0.176)
T4 23.9 3.50 (1.90–6.44; o0.001)
Mitotic rate o0.001 0.223
o1mm2 88.3 1.00 (reference) 1.00 (reference)
1–6mm2 39.7 1.97 (1.18–3.28; 0.009) 1.24 (0.68–2.26; 0.491)
46mm2 20.1 3.37 (1.95–5.81; o0.001) 1.67 (0.89–3.15; 0.111)
Ulceration
Absent 75.4 1.00 (reference) 1.00 (reference)
Present 20.1 2.71 (1.83–4.00; o0.001) 2.13 (1.41–3.23; o0.001)
Vertical growth phase
Absent 115.4 1.00 (reference) 1.00 (reference)
Present 34.6 2.90 (1.51–5.58; 0.001) 0.88 (0.35–2.17; 0.774)
Regression
Absent 40.9 1.00 (reference)
Present 53.6 0.60 (0.30–1.18; 0.137)
Microsatellites
Absent 43.2 1.00 (reference)
Present 18.5 2.45 (0.99–6.06; 0.053)
TILs
Absent 41.0 1.00 (reference)
Present 75.4 0.53 (0.19–1.44; 0.531)
Acral
Non-acral 34.6 1.00 (reference)
Acral 51.5 0.79 (0.54–1.16; 0.233)
TNM stage o0.001 o0.001
I 115.4 1.00 (reference) 1.00 (reference)
II 51.5 2.57 (1.33–4.98; 0.005) 1.56 (0.62–3.94; 0.346)
III 20.1 5.25 (2.58–10.7; o0.001) 3.55 (1.43–8.83; 0.006)
IV 8.8 17.5 (8.27–37.0; o0.001) 12.0 (4.51–32.1; o0.001)
BRAF mutation
Wild type 41.8 1.00 (reference)
Mutant type 56.1 1.15 (0.66–2.02; 0.629)
KIT mutation
Wild type 53.2 1.00 (reference) 1.00 (reference)
Mutant type 34.6 1.88 (1.08–3.25; 0.025) 2.27 (1.27–4.04; 0.005)
Increased KIT copy number
No 44.7 1.00 (reference)
Yes 27.1 1.13 (0.71–1.79; 0.601)
KIT aberration
No 56.1 1.00 (reference)
Yes 34.6 1.33 (0.90–2.00; 0.155)
Abbreviations: CI, confidence interval; HR, hazard ratio; TIL, tumor-infiltrating lymphocyte; TNM, tumor, node, metastasis.
1For 95% CIs that do not contain one, the risk was considered to be statistically significant.
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study, we aimed to determine the
incidence of melanoma subtypes in
202 Korean patients with melanomas
and to analyze BRAF mutations and KIT
aberrations (mutations and increased
copy number) in relation to clinico-
pathological features and prognosis.
We examined formalin-fixed, paraffin-
embedded specimens from 202 Korean
melanoma patients at Chonnam Na-
tional University Hospital and Hwasun
Hospital between May 1994 and July
2011. The study protocol was approved
by the institutional review board of
Chonnam National University Hwasun
Hospital. Written informed patient con-
sent was obtained, and the study was
conducted according to the Declaration
of Helsinki Principles.
Genomic DNA was extracted from
the samples. Hotspot mutations were
detected by amplification of exons 11
and 15 of the BRAF gene and exons 9,
11, 13, and 17 of the KIT gene, using
the primers shown in Supplementary
Table S5 online. To identify the BRAF
exon 15 codon 600 mutation, we per-
formed pyrosequencing using a PSQ
96MA instrument (Biotage AB, Uppsa-
la, Sweden) at room temperature with
PyroMark Gold Q96 Reagent (Qiagen,
Hilden, Germany). If the result was
negative, we sequenced BRAF exons 11
and 15. For KIT mutations, we initially
sequenced all of the samples. PCR
products purified with Expin PCR
SV (GeneAll Biotechnology, Seoul,
Korea) were directly sequenced using
ABI-PRISM Big Dye Terminator (ver.
3.1; Applied Biosystems, Foster City,
CA). KIT copy number was assessed
by quantitative real-time PCR using
GAPDH as a control gene. Relative copy
numbers were calculated by the DDCt
method (Beadling et al., 2008; Kong
et al., 2011). Statistical analyses were
performed using SPSS ver. 19.0 (SPSS,
Chicago, IL). A P-valueo0.05 was taken
to indicate statistical significance.
Of the 202 Korean melanomas, acral
melanomas (110, 54.5%) were most
common, followed by mucosal mela-
nomas (51, 25.2%) (Supplementary
Table S1 online). Non-CSD and CSD
melanomas were relatively uncommon.
BRAF mutations were detected in 24
patients (11.9%), all in exon 15; we
found no BRAF mutations in exon 11
(Supplementary Table S2 online). BRAF
mutations were most frequently de-
tected in non-CSD melanomas (12/26,
46.2%), followed by mucosal melano-
mas (7/51, 13.7%). They were less
common in acral and CSD melanomas.
The anatomical sites for BRAF-mutated
non-CSD melanomas included the
scalp, ear helix, forearm, and calf,
which are frequently affected areas of
severe sun damage in Caucasian popu-
lations. Our results are similar to those
for a Chinese Han population; the
BRAF exon 15 T1799A (V600E) muta-
tion was detected in 14.7% of 109
patients with melanomas (Qi et al.,
2011). KIT mutations were detected in
11.4% of melanomas (23/202) (Supple-
mentary Table S1 online). The KIT
mutation frequency was the highest in
CSD melanomas (3/12, 25%), followed
by acral (13/110, 11.8%) and mucosal
melanomas (3/51, 5.9%). Both BRAF
and KIT mutations were detected in
three patients with non-CSD melano-
mas. Increased KIT copy numbers were
detected in 45 patients (22.3%). In acral
and mucosal melanomas, the increased
KIT copy number frequencies were
20.9% and 29.4%, respectively.
Clinicopathological correlations of
BRAF mutations and KIT aberrations
are shown in Supplementary Table S4
online. We included only nonsynon-
ymous mutations in all statistical ana-
lysis; two BRAF mutations and six KIT
mutations were synonymous mutations
and were excluded from analysis. The
median follow-up period was 25.2
months. First, we analyzed the un-
adjusted univariate Cox proportional
hazards regression model with compre-
hensive lists of clinicopathological fea-
tures. Breslow thickness (T4), mitotic
rate, ulceration, vertical growth phase,
tumor, node, metastasis stage (I–IV), and
KIT mutations were significantly asso-
ciated with poor prognosis (Table 1). In
a subsequent multivariate analysis with
these significant covariates, except Bre-
slow thickness, using a fully adjusted
Cox proportional hazards regression
model, KIT mutations were found to
be an independent risk factor for poor
prognosis, with a hazard ratio of 2.27
and associated 95% confidence interval
of 1.27–4.04 (P¼0.005). An overall
survival curve revealed that patients
with KIT mutations had significantly
poorer survival compared with those
without KIT mutations (P¼ 0.022, Fig-
ure 1b). BRAF mutations (Figure 1a),
increased KIT copy number (Supple-
mentary Figure S1A online), and KIT
aberrations (Supplementary Figure S1B
online) were not significantly asso-
ciated with poor survival.
Most studies of KIT mutations in
melanomas have detected mutations
in exons 11, 13, 17, and 18. Mutations
in exon 9 were infrequently detected or
not studied. Exon 9 is the location of
about 15% of KIT mutations in gastro-
intestinal stromal tumors, but is known
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Figure 1. Overall survival of patients with melanoma according to BRAF and KIT mutations status.
(a) BRAF mutation status is not significantly associated with poor survival. (b) Patients with KIT mutation
have significantly poorer survival compared with those without KIT mutation. Log-rank test was
used to compare survival curves.
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to be less frequently involved in mela-
nomas (Woodman and Davies, 2010).
The efficacy of different tyrosine kinase
inhibitors may vary according to KIT
mutation status (Maleddu et al., 2011).
Surprisingly, in the present study, KIT
mutations (total 18 exons in 17 patients)
were most frequent in exon 13 (7/18,
38.9%), followed by exon 9 (5/18,
27.8%), exon 11 (3, 16.7%), and exon
17 (3, 16.7%) (Supplementary Table S3
online). The major limitation of this
study is the short follow-up period.
Long-term follow-up is needed for more
precise survival analysis.
In conclusion, we analyzed BRAF
and KIT mutations in a large number of
Korean melanomas. KITmutations were
independently linked to a poor prog-
nosis in Korean patients with melano-
mas. Patients with mutations did not
receive BRAF or tyrosine kinase inhi-
bitors in our study, and this might
have been associated with the poor
survival. We expect that these inhibi-
tors would produce effective treat-
ment responses in selected Korean
melanomas.
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